We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.25 | 2.20 | 2.30 | 2.25 | 2.25 | 2.25 | 1,365,314 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0095 | -2.37 | 12.22M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/7/2024 12:37 | It is a pivotal time coming up and the good posts are buried as ever. | hazl | |
21/7/2024 12:36 | Agree that it ought to be kept civil. | hazl | |
21/7/2024 12:35 | This is supposed to be about the company not posters. | hazl | |
21/7/2024 12:35 | I accepted your olive branch....within minutes you were nasty again. | hazl | |
21/7/2024 12:31 | I do think swearing and verbal nastiness is completely unnecessary. But he knows I think that. | hazl | |
21/7/2024 12:27 | Agreed to give me another chance?! LOL!Yes, the seething narcissist is revealed. It was an olive branch, feel free to shove it where the sun doesn't shine. | premium beeks | |
21/7/2024 12:07 | Beeks of Arabia give it break What's your problem with me? Initially i had only intended to buy around 1.5m but kept buying and ended up with far too many.I did NOT sell all the holding. I kept 500,000 which was still a lot of shares and bought another 500,000 on Friday at around 3.80p. Why don't you post some useful info for once instead of your sarcastic comments about me | z1co | |
21/7/2024 12:05 | I have been in this a long time Beeks. Z1CO hasn't. You blew your chances recently when on request, I agreed to give you another chance. | hazl | |
21/7/2024 12:03 | Well this is going to be a very interesting week or two. | hazl | |
21/7/2024 11:51 | I remain positive however. Time will tell the outcome. I tend to agree with Uxbridgearms but I have liked this company for some time as longtermers will know. | hazl | |
21/7/2024 11:47 | Perhaps he was influenced by the famous simon C? Who has also blown hot and cold, but stated that he has now bought back in, on the 19th I believe. I suppose that he is consistent with me Beeks which you are not. This company has been amazing. The share price has done leaps and bounds in the last couple of weeks, so I am not surprised that people have got emotional or that there are so many traders. You have to do what is right for yourself however, I will remind everybody. Don't risk more than you can afford to lose in any share. IMO | hazl | |
21/7/2024 11:34 | Yes, disappointing Hazl. BATA was really positive then sold and went negative.What do you think then of Z1co who, after pushing the agenda for weeks sold and then trashed the thread as he got new info on a potential delay from the company, only to 180 degree about turn when other info came to light?Can you explain the difference or show your disappointment of him? | premium beeks | |
21/7/2024 11:21 | I realised a long time ago that frequent posters on a BB cannot be trusted with their public opinion on a share. | divmad | |
21/7/2024 11:21 | "It's easy to see who is who." Indeed'I almost got drawn into the hypes due to your daily ramps. Thankfully, I do my own research. GDR is not making any profit and doesn't look like they will any time soon. Hence, my re-evaluation of the stock. The NICE news is all or nothing. Similar to red or black on roulette. GL and DYOR | batiatus | |
21/7/2024 11:19 | This is also from NICE: The UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance, that the Genedrive® CYP2C19-ID test should be used as the point-of-care test of choice in the NHS before clopidogrel administration in the management of IS and TIA patient | z1co | |
21/7/2024 11:19 | This is from NICE: In addition to being dominant in cost effectiveness models, NICE recommends the Genedrive® as the point-of-care platform of choice for CYP2C19 genotyping strategies in the NHS. The decision was based on several differentiating features of the Genedrive® technology; 1) its greater coverage of genetic variants compared to the other point-of-care system assessed, permitting increased equitable access to healthcare across ethnic populations 2) no requirement for cold-chain storage logistics 3) its ability to integrate with patient electronic healthcare systems. | z1co | |
21/7/2024 11:17 | Let me know when you've seen. | hazl | |
21/7/2024 11:05 | I can't do pms today but I would say not worth worrying about. Had to look through different means. 22 views created recently. | hazl | |
21/7/2024 11:02 | Disappointing. I thought he was ok. | hazl | |
21/7/2024 11:00 | It's easy to see who is who. On the 14th a few days ago B was singing GDR's praises . He states 'the sky is the limit' if the full approval is given! 'Batiatus - 14 Jul 2024 - 09:31:37 - 5573 of 6374 Genedrive, A Game Changer for Point of Care Testing Market? - GDR You don't seem to understand that this is in the early stages. The £100K is evidence that further supports the kits capabilities. No one would spend £100K if the product didn't work Once full recommendation is given, which officially certifies the kit, then the sky is the limit. There onwards, it would open up the rest of the UK market, as well as the US and EU markets.' imo | hazl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions